Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 9.1
edited by manuelmenendez
on 2025/01/27 23:23
Change comment: There is no comment for this version
To version 6.1
edited by manuelmenendez
on 2025/01/27 23:21
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,7 +2,8 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= //A new tridimensional diagnostic framework for CNS conditions// =
5 += **Neurodiagnoses**
6 +//A new tridimensional diagnostic framework for CNS conditions// =
6 6  
7 7  This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 8  We aim to create a structured, interpretable, and scalable diagnostic tool.
... ... @@ -15,7 +15,7 @@
15 15  (((
16 16  = What is this about and what can I find here? =
17 17  
18 -== **Overview** ==
19 +==== **Overview** ====
19 19  
20 20  The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21 21  
... ... @@ -29,7 +29,7 @@
29 29  * Integration of incomplete datasets using AI-driven probabilistic modeling.
30 30  * Stratification of patients for personalized treatment.
31 31  
32 -== **Diagnostic Axes** ==
33 +==== **Diagnostic Axes** ====
33 33  
34 34  * (((
35 35  **Axis 1: Etiology**
... ... @@ -53,11 +53,28 @@
53 53  * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
54 54  )))
55 55  
56 -== **Applications** ==
57 +==== **Case Studies** ====
57 57  
59 +1. (((
60 +**Sporadic Alzheimer’s Disease**:
61 +
62 +* Axis 1: Sporadic (ApoE4, poor sleep habits).
63 +* Axis 2: Amyloid-beta plaques, elevated NFL.
64 +* Axis 3: Right hippocampus atrophy (visual memory loss).
65 +)))
66 +1. (((
67 +**Genetic Parkinson’s Disease**:
68 +
69 +* Axis 1: Genetic (LRRK2 mutation).
70 +* Axis 2: Alpha-synuclein aggregation.
71 +* Axis 3: Substantia nigra degeneration (motor dysfunction).
72 +)))
73 +
74 +==== **Applications** ====
75 +
58 58  This system enhances:
59 59  
60 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
78 +* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
61 61  * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
62 62  
63 63  == Who has access? ==